Mirum charts positive course for hepatitis delta drug on first Phase III win

Mirium is planning to submit a BLA for brelovitug in chronic HDV in H1 2027, provided it secures a win in its other Phase III trial. The company is planning to submit a BLA for brelovitug in chronic HDV in the first half of 2027. Mirum will now await results from its second Phase III HDV study on brelovitug, AZURE-4. Credit: crystal light / Shutterstock.com. Mirum Pharmaceuticals has secured a positive outcome for the first late-stage trial on its chronic hepatitis delta virus (HDV) therapy, brelovitug – potentially poising the drug for future regulatory submissions. During the 48-week Phase IIb/III…

Source: Clinical Trials Arena